Innoviva EBIT 2010-2024 | INVA

Innoviva ebit from 2010 to 2024. Ebit can be defined as earnings before interest and taxes.
Innoviva Annual EBIT
(Millions of US $)
2023 $114
2022 $474
2021 $375
2020 $321
2019 $246
2018 $238
2017 $184
2016 $109
2015 $32
2014 $-34
2013 $-29
2012 $-25
2011 $-110
2010 $-78
2009 $-81
Innoviva Quarterly EBIT
(Millions of US $)
2024-09-30 $43
2024-06-30 $55
2024-03-31 $26
2023-12-31 $38
2023-09-30 $18
2023-06-30 $29
2023-03-31 $30
2022-12-31 $24
2022-09-30 $289
2022-06-30 $83
2022-03-31 $78
2021-12-31 $105
2021-09-30 $95
2021-06-30 $97
2021-03-31 $79
2020-12-31 $85
2020-09-30 $84
2020-06-30 $76
2020-03-31 $76
2019-12-31 $74
2019-09-30 $61
2019-06-30 $60
2019-03-31 $52
2018-12-31 $77
2018-09-30 $58
2018-06-30 $63
2018-03-31 $41
2017-12-31 $66
2017-09-30 $40
2017-06-30 $48
2017-03-31 $29
2016-12-31 $38
2016-09-30 $28
2016-06-30 $26
2016-03-31 $18
2015-12-31 $17
2015-09-30 $8
2015-06-30 $5
2015-03-31 $1
2014-12-31 $0
2014-09-30 $-10
2014-06-30 $-10
2014-03-31 $-15
2013-12-31 $19
2013-09-30 $-8
2013-06-30 $-7
2013-03-31 $-33
2012-12-31 $-30
2012-09-30 $-33
2012-06-30 $-36
2012-03-31 $86
2011-12-31 $-36
2011-09-30 $-29
2011-06-30 $-24
2011-03-31 $-21
2010-12-31 $-18
2010-09-30 $-20
2010-06-30 $-19
2010-03-31 $-21
2009-12-31 $-21
2009-09-30 $-21
2009-06-30 $-21
2009-03-31 $-18
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.263B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80